BRPI0912245A2 - composto, prodroga, medicamento, métodos de suprimir produção de açúcar em um mamífero e para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso do composto - Google Patents
composto, prodroga, medicamento, métodos de suprimir produção de açúcar em um mamífero e para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso do compostoInfo
- Publication number
- BRPI0912245A2 BRPI0912245A2 BRPI0912245A BRPI0912245A BRPI0912245A2 BR PI0912245 A2 BRPI0912245 A2 BR PI0912245A2 BR PI0912245 A BRPI0912245 A BR PI0912245A BR PI0912245 A BRPI0912245 A BR PI0912245A BR PI0912245 A2 BRPI0912245 A2 BR PI0912245A2
- Authority
- BR
- Brazil
- Prior art keywords
- mammal
- compound
- prodrug
- prophylaxis
- diabetes
- Prior art date
Links
- 241000124008 Mammalia Species 0.000 title 2
- 150000001875 compounds Chemical class 0.000 title 2
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Furan Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008055250 | 2008-03-05 | ||
| JP2009025511 | 2009-02-06 | ||
| PCT/JP2009/054095 WO2009110520A1 (ja) | 2008-03-05 | 2009-03-04 | 複素環化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0912245A2 true BRPI0912245A2 (pt) | 2019-09-24 |
Family
ID=41056073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0912245A BRPI0912245A2 (pt) | 2008-03-05 | 2009-03-04 | composto, prodroga, medicamento, métodos de suprimir produção de açúcar em um mamífero e para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso do composto |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8436043B2 (pt) |
| EP (1) | EP2251326A4 (pt) |
| JP (1) | JP5465658B2 (pt) |
| KR (1) | KR101616140B1 (pt) |
| CN (1) | CN102015641B (pt) |
| AU (1) | AU2009220615B2 (pt) |
| BR (1) | BRPI0912245A2 (pt) |
| CA (1) | CA2717138A1 (pt) |
| CO (1) | CO6321238A2 (pt) |
| CR (1) | CR11688A (pt) |
| DO (1) | DOP2010000267A (pt) |
| EA (1) | EA019752B1 (pt) |
| EC (1) | ECSP10010526A (pt) |
| GE (1) | GEP20135844B (pt) |
| IL (1) | IL207757A (pt) |
| MA (1) | MA32171B1 (pt) |
| MX (1) | MX2010009736A (pt) |
| MY (1) | MY158982A (pt) |
| NZ (1) | NZ588011A (pt) |
| WO (1) | WO2009110520A1 (pt) |
| ZA (1) | ZA201006511B (pt) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| CN102838599A (zh) | 2006-05-04 | 2012-12-26 | 贝林格尔.英格海姆国际有限公司 | 多晶型 |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP2210876B1 (en) | 2007-11-01 | 2015-05-20 | Takeda Pharmaceutical Company Limited | Heterocyclic compound as glucagon antagonist |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| JP5535931B2 (ja) * | 2008-10-27 | 2014-07-02 | 武田薬品工業株式会社 | 二環性化合物 |
| EA022310B1 (ru) | 2008-12-23 | 2015-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Солевые формы органического соединения |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| WO2010104194A1 (en) | 2009-03-10 | 2010-09-16 | Takeda Pharmaceutical Company Limited | Benzofuran derivatives |
| WO2011027849A1 (ja) * | 2009-09-04 | 2011-03-10 | 武田薬品工業株式会社 | 複素環化合物 |
| NZ599298A (en) | 2009-11-27 | 2014-11-28 | Boehringer Ingelheim Int | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| US8642770B2 (en) * | 2010-01-06 | 2014-02-04 | Takeda Pharmaceutical Company Limited | Indole derivative |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2011138421A1 (en) | 2010-05-05 | 2011-11-10 | Boehringer Ingelheim International Gmbh | Combination therapy |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| NZ603319A (en) | 2010-06-24 | 2015-04-24 | Boehringer Ingelheim Int | Diabetes therapy |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| MX2013006768A (es) | 2010-12-23 | 2013-07-22 | Pfizer | Moduladores de receptor de glucagon. |
| ES2597972T3 (es) | 2011-02-08 | 2017-01-24 | Pfizer Inc | Modulador del receptor de glucagón |
| CA2841552C (en) | 2011-07-15 | 2020-06-23 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
| RU2013157388A (ru) | 2011-07-22 | 2015-08-27 | Пфайзер Инк. | Хинолинильные модуляторы глюкагонового рецептора |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US9073864B2 (en) | 2012-03-29 | 2015-07-07 | Takeda Pharmaceutical Company Limted | Aromatic ring compound |
| EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
| US20130303554A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in sirs and/or sepsis |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
| WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
| KR102021114B1 (ko) * | 2017-01-24 | 2019-09-11 | 주식회사 엘지화학 | 페놀의 정제 방법 |
| DK3573611T3 (da) * | 2017-01-24 | 2022-04-11 | Alphala Co Ltd | Amidforbindelser og anvendelse deraf |
| WO2020167624A1 (en) | 2019-02-13 | 2020-08-20 | Ptc Therapeutics, Inc. | Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia |
| MX2021009667A (es) | 2019-02-13 | 2021-12-10 | Ptc Therapeutics Inc | Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomía familiar. |
| GB201909191D0 (en) * | 2019-06-26 | 2019-08-07 | Ucb Biopharma Sprl | Therapeutic agents |
| GB201909190D0 (en) * | 2019-06-26 | 2019-08-07 | Ucb Biopharma Sprl | Therapeutic agents |
| EP3766879A1 (en) | 2019-07-19 | 2021-01-20 | Basf Se | Pesticidal pyrazole derivatives |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| US20250382305A1 (en) * | 2022-06-22 | 2025-12-18 | Ptc Therapeutics, Inc. | Compounds for treating spinocerebellar ataxia type 3 |
| WO2025257413A1 (en) | 2024-06-13 | 2025-12-18 | Syngenta Crop Protection Ag | Pecticidally active dihydroazole derivatives |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4793717A (en) | 1982-05-06 | 1988-12-27 | Minnesota Mining And Manufacturing Company | Device for visually indicating a pressure or temperature condition |
| KR100659007B1 (ko) | 1999-02-10 | 2007-02-28 | 미츠비시 웰파마 가부시키가이샤 | 아미드 화합물 및 그 의약으로서의 용도 |
| BR0010651A (pt) | 1999-05-17 | 2002-03-19 | Novo Nordisk As | Composto, uso de um composto, composição farmacêutica, e, método para o tratamento e/ou prevenção de distúrbios ou de doenças mediadas por uma ação antagonìstica de glucagon |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| ATE479429T1 (de) | 2000-04-28 | 2010-09-15 | Takeda Pharmaceutical | Antagonisten des melanin-konzentrierenden hormons |
| CA2408913A1 (en) | 2000-05-16 | 2001-11-22 | Takeda Chemical Industries, Ltd. | Melanin-concentrating hormone antagonist |
| US7241785B2 (en) | 2001-03-23 | 2007-07-10 | Takeda Pharmaceutical Company Limited | Five-membered heterocyclic alkanoic acid derivative |
| EP1463715A1 (en) * | 2001-12-03 | 2004-10-06 | Novo Nordisk A/S | Novel glucagon antagonists |
| US20060148858A1 (en) | 2002-05-24 | 2006-07-06 | Tsuyoshi Maekawa | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity |
| DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
| JP2006500325A (ja) * | 2002-06-27 | 2006-01-05 | ノボ ノルディスク アクティーゼルスカブ | 新規なグルカゴンアンタゴニスト |
| WO2004045616A1 (en) | 2002-11-21 | 2004-06-03 | Pharmacia & Upjohn Company Llc | N-(4-(piperazin-1-yl)-phenyl-2-oxazolidinone-5-carboxamide derivates and related compounds as antibacterial agents |
| US7572922B2 (en) * | 2003-01-27 | 2009-08-11 | Merck & Co., Inc. | Substituted pyrazoles, compositions containing such compounds and methods of use |
| ES2350837T3 (es) * | 2003-05-01 | 2011-01-27 | Bristol-Myers Squibb Company | Compuestos de pirazol-amida sustituidos con arilo útiles como inhibidores de quinasas. |
| CN1784226A (zh) * | 2003-05-09 | 2006-06-07 | 麦克公司 | 苯并咪唑化合物、含有苯并咪唑化合物的组合物以及使用方法 |
| CN1964947A (zh) | 2004-06-04 | 2007-05-16 | 默克公司 | 吡唑衍生物、包含其的组合物及其用法 |
| RU2346996C2 (ru) | 2004-06-29 | 2009-02-20 | ЮРОПИЭН НИКЕЛЬ ПиЭлСи | Усовершенствованное выщелачивание основных металлов |
| JP2008505905A (ja) * | 2004-07-07 | 2008-02-28 | メルク エンド カムパニー インコーポレーテッド | ピラゾールアミド誘導体、こうした化合物を含有する組成物および使用方法 |
| CA2574147A1 (en) * | 2004-07-22 | 2006-02-09 | Linda Brockunier | Substituted pyrazoles, compositions containing such compounds and methods of use |
| JP2006112549A (ja) | 2004-10-15 | 2006-04-27 | Jtekt Corp | 自在継手 |
| CN101146762A (zh) | 2005-03-21 | 2008-03-19 | 默克公司 | 取代的芳基和杂芳基衍生物 |
| JP5094394B2 (ja) | 2005-04-20 | 2012-12-12 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| EP1895898B1 (en) | 2005-06-29 | 2011-02-16 | Compumedics Limited | Sensor assembly with conductive bridge |
| JP5577006B2 (ja) | 2005-07-01 | 2014-08-20 | 味の素株式会社 | 迅速スクリーニング方法及び該方法で得られた微生物 |
| CA2623958C (en) | 2005-09-30 | 2013-05-28 | Banyu Pharmaceutical Co., Ltd. | 2-heteroaryl-substituted indole derivative |
| SI1951661T1 (sl) * | 2005-11-17 | 2012-11-30 | Lilly Co Eli | Antagonisti glukagonskega receptorja priprava interapevtske uporabe |
| WO2007089031A1 (en) | 2006-02-01 | 2007-08-09 | Takeda Pharmaceutical Company Limited | Piperidine derivatives as tachykinin receptor antagonists |
| TW200821284A (en) | 2006-10-03 | 2008-05-16 | Merck & Co Inc | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| EP2210876B1 (en) | 2007-11-01 | 2015-05-20 | Takeda Pharmaceutical Company Limited | Heterocyclic compound as glucagon antagonist |
| WO2010000020A1 (en) | 2008-06-30 | 2010-01-07 | Cathrx Ltd | A catheter |
-
2009
- 2009-03-04 BR BRPI0912245A patent/BRPI0912245A2/pt not_active IP Right Cessation
- 2009-03-04 GE GEAP2009011962 patent/GEP20135844B/en unknown
- 2009-03-04 CA CA2717138A patent/CA2717138A1/en not_active Abandoned
- 2009-03-04 KR KR1020107022118A patent/KR101616140B1/ko not_active Expired - Fee Related
- 2009-03-04 MY MYPI2010004008A patent/MY158982A/en unknown
- 2009-03-04 US US12/920,973 patent/US8436043B2/en not_active Expired - Fee Related
- 2009-03-04 EA EA201071032A patent/EA019752B1/ru not_active IP Right Cessation
- 2009-03-04 WO PCT/JP2009/054095 patent/WO2009110520A1/ja not_active Ceased
- 2009-03-04 JP JP2010501939A patent/JP5465658B2/ja not_active Expired - Fee Related
- 2009-03-04 AU AU2009220615A patent/AU2009220615B2/en not_active Ceased
- 2009-03-04 EP EP09717906A patent/EP2251326A4/en not_active Withdrawn
- 2009-03-04 MX MX2010009736A patent/MX2010009736A/es active IP Right Grant
- 2009-03-04 NZ NZ588011A patent/NZ588011A/en not_active IP Right Cessation
- 2009-03-04 CN CN200980116371.3A patent/CN102015641B/zh not_active Expired - Fee Related
-
2010
- 2010-08-23 IL IL207757A patent/IL207757A/en not_active IP Right Cessation
- 2010-09-03 DO DO2010000267A patent/DOP2010000267A/es unknown
- 2010-09-10 ZA ZA2010/06511A patent/ZA201006511B/en unknown
- 2010-09-23 CR CR11688A patent/CR11688A/es unknown
- 2010-09-29 MA MA33207A patent/MA32171B1/fr unknown
- 2010-10-04 CO CO10122832A patent/CO6321238A2/es active IP Right Grant
- 2010-10-05 EC EC2010010526A patent/ECSP10010526A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO6321238A2 (es) | 2011-09-20 |
| EA019752B1 (ru) | 2014-06-30 |
| EA201071032A1 (ru) | 2011-06-30 |
| KR20100126470A (ko) | 2010-12-01 |
| US20120053173A1 (en) | 2012-03-01 |
| DOP2010000267A (es) | 2010-09-30 |
| JPWO2009110520A1 (ja) | 2011-07-14 |
| JP5465658B2 (ja) | 2014-04-09 |
| US20120270865A2 (en) | 2012-10-25 |
| EP2251326A4 (en) | 2011-08-31 |
| CA2717138A1 (en) | 2009-09-11 |
| IL207757A0 (en) | 2010-12-30 |
| MA32171B1 (fr) | 2011-03-01 |
| ZA201006511B (en) | 2011-11-30 |
| KR101616140B1 (ko) | 2016-04-27 |
| NZ588011A (en) | 2012-06-29 |
| GEP20135844B (en) | 2013-06-10 |
| CN102015641A (zh) | 2011-04-13 |
| US8436043B2 (en) | 2013-05-07 |
| WO2009110520A1 (ja) | 2009-09-11 |
| AU2009220615A2 (en) | 2010-11-11 |
| IL207757A (en) | 2015-07-30 |
| AU2009220615A1 (en) | 2009-09-11 |
| AU2009220615B2 (en) | 2013-12-19 |
| MX2010009736A (es) | 2010-09-30 |
| CN102015641B (zh) | 2014-01-01 |
| ECSP10010526A (es) | 2010-11-30 |
| MY158982A (en) | 2016-11-30 |
| EP2251326A1 (en) | 2010-11-17 |
| CR11688A (es) | 2010-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0915084A2 (pt) | composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, métodos para a profilaxia ou tratamento de um estado de doença ou uma condição e de câncer | |
| BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
| BR112013013435A2 (pt) | composto, composição farmacêutica, uso de um composto, método para a profilaxia ou tratamento de um estado ou condição de doença mediados por uma cinase de fgfr, e, processo para a preparação de um composto. | |
| BRPI1013984A2 (pt) | composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto. | |
| BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
| BR112014010179A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição | |
| BR112014010183A2 (pt) | composto, composição farmacêutica, uso de um composto, método para a profilaxia ou tratamento de um estado ou uma condição de doença mediada por uma fgfr cinase | |
| BRPI0924427A2 (pt) | composição farmacêutica de liberação controlada, seu processo de preparação e uso da mesma | |
| BRPI0910282A2 (pt) | Composto oxadiazo-antraceno para o tratamento de diabetes | |
| BRPI1009381A2 (pt) | compostos, composição farmacêutica, método para tratar doença ou condição associada com função de trap1 em sujeito em necessidade do mesmo e uso de compostos e composição farmacêutica | |
| BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
| BR112015003332A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| BRPI0917705A2 (pt) | composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto | |
| BR112015003398A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| BRPI0917119A2 (pt) | composto, composição farmacêutica, métodos para inibir a poli(adp-ribose) polimerase em um paciente, para tratar uma doença, uso de um composto, e, artigo de fabricação. | |
| BRPI0819755A2 (pt) | composto, composição farmacêutica, processos para a preparação de um composto e de uma composição farmacêutica, uso de um composto, e, método para tratar ou reduzir o risco de uma doença ou uma condição inflamatória | |
| BRPI0812851A2 (pt) | Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto | |
| BRPI1015983A2 (pt) | composto, uso do composto, método para tratar um paciente, e, composição farmacêutica. | |
| PL3181134T3 (pl) | Bifidobakterie do leczenia cukrzycy i stanów pokrewnych | |
| BRPI1013763A2 (pt) | Composto ou sal do mesmo, prodroga, composição farmacêutica, agente diminuidor da proteína de ligação de retinol 4, agente para a profilaxia ou tratamento de diabetes, e, uso de um composto | |
| BRPI0716134A2 (pt) | tratamento de combinaÇço para diabetes mellitus | |
| BRPI0907976A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
| BRPI0921317A2 (pt) | composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero | |
| BRPI1013396A2 (pt) | composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto. | |
| BR112012000502A2 (pt) | terapia de combinação para o tratamento de diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |